Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886859 | 0.76 | POLG (0.41) | P2RY2P2RY4P2RY6P2RX1P2RX3 | |
| SCHEMBL3485976 | 0.76 | P2RY6 (0.41) | P2RY2P2RY4P2RY6POLA1P2RX3 | |
| SCHEMBL5708922 | 0.76 | POLG (0.48) | P2RY2P2RY4P2RY6 | |
| SCHEMBL10900419 | 0.66 | POLG (0.49) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6038233 | 0.66 | POLG (0.50) | P2RY2P2RY4P2RY6 | |
| SCHEMBL28293726 | 0.65 | P2RY6 (0.58) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL5191085 | 0.65 | POLB (0.50) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL597307 | 0.64 | POLG (0.49) | P2RY2P2RY4P2RY6 | |
| SCHEMBL8436036 | 0.64 | P2RY6 (0.58) | P2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL95680 | 0.64 | P2RY6 (0.54) | P2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001032928-A9 | METHODS OF DETERMINING INDIVIDUAL HYPERSENSITIVITY TO AN AGENT | PHASE 1 MOLECULAR TOXICOLOGY (US) | 2002-05-16 | — | — | WO | disclosed |
| WO-2001032928-A2 | METHODS OF DETERMINING INDIVIDUAL HYPERSENSITIVITY TO AN AGENT | PHASE-1 MOLECULAR TOXICOLOGY (US) | 2001-05-10 | — | — | WO | disclosed |